JP2025501307A5 - - Google Patents

Info

Publication number
JP2025501307A5
JP2025501307A5 JP2024539913A JP2024539913A JP2025501307A5 JP 2025501307 A5 JP2025501307 A5 JP 2025501307A5 JP 2024539913 A JP2024539913 A JP 2024539913A JP 2024539913 A JP2024539913 A JP 2024539913A JP 2025501307 A5 JP2025501307 A5 JP 2025501307A5
Authority
JP
Japan
Prior art keywords
seq
region
cancer
bispecific molecule
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082628 external-priority patent/WO2023130073A2/en
Publication of JP2025501307A publication Critical patent/JP2025501307A/ja
Publication of JP2025501307A5 publication Critical patent/JP2025501307A5/ja
Pending legal-status Critical Current

Links

JP2024539913A 2021-12-31 2022-12-30 最初の細胞を標的とする二重特異性分子 Pending JP2025501307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163295681P 2021-12-31 2021-12-31
US63/295,681 2021-12-31
PCT/US2022/082628 WO2023130073A2 (en) 2021-12-31 2022-12-30 Bispecific molecules to target the first cell

Publications (2)

Publication Number Publication Date
JP2025501307A JP2025501307A (ja) 2025-01-17
JP2025501307A5 true JP2025501307A5 (cg-RX-API-DMAC7.html) 2026-01-13

Family

ID=87000357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539913A Pending JP2025501307A (ja) 2021-12-31 2022-12-30 最初の細胞を標的とする二重特異性分子

Country Status (6)

Country Link
US (1) US20250051475A1 (cg-RX-API-DMAC7.html)
EP (1) EP4456918A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025501307A (cg-RX-API-DMAC7.html)
CN (1) CN118510539A (cg-RX-API-DMAC7.html)
AU (1) AU2022426854A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023130073A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025085511A1 (en) * 2023-10-18 2025-04-24 University Of Washington Systems and methods for polymer-mediated activation of engineered cells
WO2025264955A1 (en) * 2024-06-21 2025-12-26 Tfc Therapeutics, Inc. Multispecific proteins and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
US20150094224A1 (en) * 2010-05-04 2015-04-02 Paul Walfish Methods for the diagnosis or prognosis of breast cancer
WO2012122228A2 (en) * 2011-03-07 2012-09-13 Temple University - Of The Commonwealth System Of Higher Education Biomarkers of chronic obstructive pulmonary disease
JP2015515264A (ja) * 2012-03-12 2015-05-28 スカラテック メディカル アーベー 疾患の処置のためのキメラタンパク質
CN112513081A (zh) * 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
CA3110837A1 (en) * 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
US11634501B2 (en) * 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
Yang et al. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth
Guo et al. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2009505676A5 (cg-RX-API-DMAC7.html)
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2016503295A5 (cg-RX-API-DMAC7.html)
JP2021502810A5 (cg-RX-API-DMAC7.html)
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP2019533475A5 (cg-RX-API-DMAC7.html)
JP2021511811A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2020522474A5 (cg-RX-API-DMAC7.html)
RU2009115363A (ru) Антагонисты рецепторов для лечения метастатического рака
JP2011505146A5 (cg-RX-API-DMAC7.html)
JP2015529641A5 (cg-RX-API-DMAC7.html)
JP2017521054A5 (cg-RX-API-DMAC7.html)
JP2024504471A5 (cg-RX-API-DMAC7.html)
JP2008508858A5 (cg-RX-API-DMAC7.html)
Wang et al. NKG2D immunoligand rG7S-MICA enhances NK cell-mediated immunosurveillance in colorectal carcinoma
JP2019512210A5 (cg-RX-API-DMAC7.html)
Abushukair et al. Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance
Hong et al. The role of cancer‐associated fibroblasts in the tumour microenvironment of urinary System